Promoting Awareness of Current Trials and Encouraging Public Engagement in Dementia Research (NIHR / Join Dementia Research)


The “Join Dementia Research” website has been designed to assist people to learn more about dementia research which is ongoing, whether in their local areas or across the UK. This service offers the public opportunities to get involved in dementia research, and makes it easier to connect with researchers. It should be particularly of interest to people with dementia, and their families, who would like to participate in studies.

” …the National Institute for Health Research (NIHR) in partnership with Alzheimers Research UK and the Alzheimers Society have developed Join dementia Research, a new service which allows people to register their interest in participating in dementia research and be matched to suitable studies”.

Read more: Join Dementia Research: register your interest in dementia research. About this service. NIHR.

During December 2014 the National Institute of Health Research (NIHR), in partnership with Alzheimer’s Research UK and the Alzheimer’s Society, ran an original festive public awareness and engagement campaign, called the “Advent Calendar”: 24 Days of Dementia Research. This involved a day-by-day introduction to 24 different clinical trials / research studies which happen, currently, to be recruiting members of the public to participate in research.

These 24 trials / studies are listed alphabetically below, with a brief description of each, plus links to further details and contact information:

The AFFECT Study involves collaboration between researchers in Northern Ireland and staff at the Dementias and Neurodegeneration Specialty in England. The AFFECT Study is investigating whether medications (such as Amlodipine) used for treating the symptoms of high blood pressure and high cholesterol might also be effective in reducing the symptoms of Subcortical Ischemic Vascular Dementia (SIVD). SIVD is the most common form of Vascular Dementia.

The DAPA Study involves investigating whether physical activity might have any role in slowing the progression of dementia once it has already started. The DAPA: Dementia and Physical Activity Trial is based at the University of Warwick’s Warwick Medical School. It will study the effects of physical activity (exercise) on cognition (memory and understanding) and function (daily activities) in people with mild to moderate dementia living in the community.

The “GE180” Study involves exploring new ways of imaging and mapping the brain, and monitoring how the central nervous system is affected by dementia. GE180 is a chemical devised by researchers which latches onto the Amyloid proteins, and this tracer / marker enables researchers to trace activity and damage to nerve cells. The aim of the GE180 Study is to develop more accurate methods of diagnosing Alzheimer’s Disease and other dementias, and measuring the effects of these conditions, with the possibility of determining how effective potential treatments prove to be in practice.

The GREAT Trial, based at Bangor University, is investigating whether talking therapy can help people cope better with memory problems. The GREAT Study (short for Goal­-oriented cognitive Rehabilitation in EArly ­sTage dementia) is designed to establish whether Cognitive Rehabilitation Therapy is beneficial for people attending Memory Clinics (and for their friends and family members).

The “IDEAL” Study aims to provide evidence to guide policy and practice regarding helping people live well with dementia. The IDEAL Study, based at Bangor University, will investigate the factors which help (or hinder) people with dementia to maintain a good level of well-being and quality of life.

The “LMTM” Study concerns a potential treatment for the rare form of dementia called Behavioural Frontotemporal Dementia (bvFTD). It is understood that protein deposits can build up in the brain, resulting in brain cell death. The aim of the LMTM Study, run by Dementia Research Centre (DRC) at University College London, is to establish whether the chemical compound leuco-methylthioninium (LMTM) might cause such protein deposits to break apart, with the possible result of slowing of the progression of bvFTD.

The “LonDownS” Study is based at University College London. The London Down Syndrome Consortium (LonDownS) is investigating the factors influencing why a disproportionately high proportion of people with Down Syndrome develop Alzheimer’s Disease later in life.

The Neuroinflammation and Amyloid Study is examining, in-depth, what happens to the brain from the earliest stages of Mild Cognitive Impairment (MCI). The hypothesis behind the Neuroinflammation and Amyloid Study is that proteins causing inflammation of the brain could be a possible cause of neurodegeneration and dementia.

The PREVENT Study is investigating possibilities for the prevention of dementia through environmental interventions. The PREVENT Study is based at Imperial College London.

The PROTECT Study is a dementia research study run by the Institute of Psychiatry at King’s College London. The PROTECT Study aims to improve understanding of how the brain ages, with an emphasis on discovering why some people are more likely to develop dementia.

The Young Onset Alzheimer’s Disease (YOAD) Study concerns the 40,000 people per year who develop symptoms before age 65. The Young Onset Alzheimer’s Disease (YOAD) Study is based at the University College London’s Dementia Research Centre, and is investigating better diagnosis and improving understanding of changes in the brain which occur during the development of Alzheimer’s Disease.

Due Credit

The “Join Dementia Research” website was brought to our attention by kind permission of the Lewy Body Society.

About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in Alzheimer's Society, Alzheimer’s Research UK, Charitable Bodies, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Social Workers (mostly), Local Interest, Management of Condition, Models of Dementia Care, National, NIHR, Non-Pharmacological Treatments, Northern Ireland, Parkinson's Disease, Patient Care Pathway, Patient Information, Pharmacological Treatments, Practical Advice, Quick Insights, UK, Universal Interest, Wales and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.